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Streptococcus pneumoniae bacteria can be characterized into over 90 serotypes
according to the composition of their polysaccharide capsules. Some serotypes
are common in nasopharyngeal carriage whereas others are associated
with invasive disease, but when carriage serotypes do invade disease is
often particularly severe. It is unknown whether disease severity is due
directly to the capsule type or to other virulence factors. Here, we used a clini-
cal pneumococcal isolate and its capsule-switch mutants to determine the
effect of capsule, in isolation from the genetic background, on severity of
meningitis in an infant rat model. We found that possession of a capsule
was essential for causing meningitis. Serotype 6B caused significantly more
mortality than 7F and this correlated with increased capsule thickness in the
cerebrospinal fluid (CSF), a stronger inflammatory cytokine response in the
CSF and ultimately more cortical brain damage. We conclude that capsule
type has a direct effect on meningitis severity. This is an important consider-
ation in the current era of vaccination targeting a subset of capsule types
that causes serotype replacement.1. Background
Streptococcus pneumoniae is one of the most important human pathogens, res-
ponsible for 14.5 million episodes of serious disease, including meningitis,
pneumonia and sepsis, per year and 826 000 deaths in children under 5 years of
age [1]. It is the most frequent cause of bacterial meningitis in children and is par-
ticularly associated with severe disease with a high mortality rate and brain
damage leading to neurological sequelae in up to 50%of survivors [2–5]. The bac-
teria may be surrounded by one of more than ninety known types of
polysaccharide capsule that determine the serotype and some ofwhich are targets
for the vaccines currently available [6]. While some serotypes are common,
usually asymptomatic, colonizers of the human nasopharynx, others are associ-
ated with invasive disease [7–9]. However, when serotypes usually associated
with colonization do invade, the disease they cause tends to be particularly
severe [10,11]. Here, we address the question of whether capsule type affects
severity of disease directly.
In vivomodels of experimentalmeningitis have shown that strains vary in their
ability to cause disease, but this has often been attributed to the cell wall rather
than the capsule [12,13]. In such studies where the strains differ in serotype and
genetic background, it is difficult to conclude which factor(s) is responsible for
differences in the severity of resulting disease. Another group has proposed that
the capsule serotype, rather than the genetic background, is the most important
factor for determining the course and severity of pneumococcal meningitis [14].
In order to study the effect of capsule in isolation from the genetic background,
we produced mutants in which the capsule operon had been deleted or replaced
by that of another strain [15]. Switching serotype has been shown previously to
rsob.royalsocietypublishing.or
2
 on April 5, 2016http://rsob.royalsocietypublishing.org/Downloaded from change accessibility of protein ligands leading to differences in
binding to epithelial cells and virulence in the respiratory tract
[16] and virulence in a murine intraperitoneal infection model
and a chinchilla otitis media model [17,18], but the effect on
meningitis is unknown. Our aim in this studywas to determine
whether changing the capsule type of a pneumococcal strain
alone would change the disease severity in an infant rat menin-
gitis model as determined by the ability of the bacteria to
multiply and induce an inflammatory cerebrospinal fluid
(CSF) response, brain damage and mortality.g
Open
Biol.6:1502692. Material and methods
2.1. Bacterial strains
A clinical nasopharyngeal isolate of S. pneumoniae (106.66,
serotype 6B) was collected during a nationwide surveillance
programme [8,19]. The capsule operon was removed and
replacedwith a Janus cassette [20,21] creatingnon-encapsulated
mutant 106.66Janus. The Janus cassettewas then replaced by its
own capsule operon tomake backtransformant 106.66cps106.66
(serotype 6B) or the capsule operon of another nasopharyngeal
clinical isolate, 208.41, to produce mutant 106.66cps208.41 (ser-
otype 7F), or clinical isolate B109.15 (isolated from the blood of a
patient with pneumonia) to produce mutant 106.66cpsB109.15
(serotype 7F) as described previously [15]. Visualization of cap-
sule thickness was performed by fluorescence isothiocyanate
(FITC)-dextran exclusion assay as described previously [15]
where the zone of exclusion of FITC-dextran (2000 kDa,
Sigma) indicates the polysaccharide thickness.
2.2. Infant rat model of pneumococcal meningitis
Awell-established infant rat model of bacterial meningitis [22]
was modified as follows. The bacteria were used in the animal
model without prior passage in vivo. Litters of 12 nursing
Wistar rats with their dams were obtained from Charles
River (Sulzfeld, Germany) and acclimatized for 5 days.
Eleven-day-old rats weighing 27.1+8.3 g were infected intra-
cisternally with 10 ml 0.85% NaCl containing 2.5  106 colony
forming units (CFU) ml21 live S. pneumoniae. Animals were
randomly assigned to receive bacterial strain 106.66 (n ¼ 36),
106.66Janus (n ¼ 6), 106.66cps106.66 (n ¼ 6), 106.66cps208.41
(n ¼ 30) or 106.66cpsB109.15 (n ¼ 6). Bacterial meningitis was
confirmed by quantitative analysis of bacterial cultures in
samples of CSF at 21 hours post-infection (hpi), when the rats
developed symptomatic disease. Antibiotic therapy with cef-
triaxone (Rocephinew, Roche Pharma, Basel, Switzerland;
100 mg kg21 d21, i.p.) was administered at 21 and 29 hpi.
To assess severity of disease, the rats were weighed and
examined clinically at 0, 21, 29 and 45 hpi and scored as
described previously [22]. Animals not able to stand upright
were immediately sacrificed by an overdose of pentobarbital
(Esconarkon, Streuli, Uznach, Switzerland; 150 mg kg21, i.p.)
forethical reasons. Spontaneousmortalitywas alsodocumented.
Punctures of the cisterna magna were performed to obtain
CSF using a 30-gauge needle at 21 and 45 hpi. CSF samples
not used for bacterial titres or to visualize capsule thickness
were centrifuged at 16 000g at 48C for 10 min and the super-
natants frozen at 2808C for later determination of cytokine
concentrations. Animals were sacrificed with an overdose of
pentobarbital (150 mg kg21) at 45 hpi and perfused with 4%paraformaldehyde (PFA) in PBS before the brains were
removed and fixed in PFA for histological analysis.
2.3. Cytokine measurement in cerebrospinal fluid
The concentrations of the cytokines IL-6, IL-1b, TNFa, IL-10
and IFNg in the CSF samples were determined using the
microsphere-based multiplex assays (MILLIPLEXw MAP
kit, rat cytokine/chemokine magnetic bead panel, Millipore
Corporation, Billerica, MA) as described previously [23].
2.4. Histomorphometrical analysis of brain damage
Brain damage was quantified as previously described in ani-
mals sacrificed at 45 hpi [22,23]. Volume of cortical damage
(areas of decreased neuronal density or cortical necrosis) was
expressed as a percentage of the total cortical volume investi-
gated in at least 16 brain sections per animal. Apoptosis in
the hippocampus was quantified by counting cells showing
features of apoptosis (condensed, fragmented dark nuclei,
apoptotic bodies) in four slices spanning the hippocampus of
both hemispheres. Cells were counted in three fields of view
in each of the two blades of the dentate gyrus and a mean
value per animal was calculated.
2.5. Preparation of bacteria and measurement
of growth
Bacteria were prepared for inoculation by growing to mid-log
phase in brain heart infusion broth (BHI; Becton Dickinson
and Company, le Pont de Claix, France). To quantify bacterial
growth, CFU were quantified. Serial dilutions of CSF samples
from infected rats were made in 0.85% NaCl, plated out
onto CSBA plates and incubated overnight at 378C with 5%
CO2. CFU were counted the next day.
2.6. Statistical analysis
Statistical analyseswere performedusingGraphPad PRISM soft-
ware (PRISM v. 6 for WINDOWS, GraphPad Software Inc., San
Diego, CA). The D’Agostino & Pearson omnibus normality
test was used to discriminate between data following a
normal Gaussian distribution or not. An unpaired Student’s
t-test was used for normally distributed data; otherwise,
Mann–Whitney test was applied. Spearman correlations
were calculated to obtain r-values. Mortality rates were calcu-
lated using log-rank (Mantel–Cox) test for significance based
on successfully infected rats and numbers of animals sacrificed
due to ethical reasons or dying spontaneously. A value of p,
0.05, two-tailed, was considered statistically significant.3. Results
3.1. Serotype 6B capsule was associated with greater
mortality due to meningitis than serotype 7F
Infant ratswere inoculated intracisternallywitheitherawild-type
clinical pneumococcal isolate, 106.66 (serotype 6B; n ¼ 36), its
non-encapsulated mutant (106.66Janus; n¼ 6) or mutant
106.66cps208.41 (n¼ 30) in which the 6B capsule has been
replaced by a capsule of serotype 7F. The bacterial strains were
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Figure 1. Clinical parameters assessed during acute bacterial meningitis in
animals infected by intracisternal inoculation with pneumococci. Switching
the capsule of wild-type strain 106.66 from serotype 6B to 7F (creating cap-
sule switch mutant 106.66cps208.41) caused (a) a significant increase in
survival rates over 45 h ( p, 0.0001) and (b) a significant reduction in
severe disease (higher clinical score) at 21 h ( p, 0.0001).
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Figure 2. Cortical injury was quantified in rats that survived to 45 hpi.
(a) Histology section of the brain of a rat exposed to strain 106.66 (serotype
6B), arrow indicates region of cortical damage. (b) The volume of cortical
injury was significantly less in rats infected with the capsule switch
mutant 106.66cps208.41 (serotype 7F) than with its serotype 6B parent
strain, 106.66 ( p ¼ 0.0006).
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and 7F strains were able to establish an infection in all rats,
with the exception of one rat that received the 7F strain.However,
no bacteria could be recovered from the CSF of rats that received
the non-encapsulated mutant 106.66Janus and they exhibited no
signs of disease.Mean bacterial titre recovered fromCSFat 21 hpi
was 7.1 108 CFU ml21 for strain 106.66 (6B) and 1.7
108 CFU ml21 for strain 106.66cps208.41 (7F). This was not sig-
nificantly different (p¼ 0.23). However, the value for 106.66
may be an underestimate as it does not include values for the
rats that died earlier than 21 hpi, which may have had higher
titres. The same pattern of slightly higher titre of 6B than 7F in
CSF at 21 hpiwas also seen for the experiment shown in the elec-
tronic supplementary material, figure S1, with a mean of 7.9 
108 CFU ml21 for the backtransformant 106.66cps106.66 (6B)
and 3.3  107 CFU ml21 for a different serotype 7F capsule
switch mutant 106.66cpsB109.15 (7F).
Survival of the rats over 45 hpi was significantly greater for
those which had received the 7F serotype strain than those
which received the strain of serotype 6B (p, 0.0001;
figure 1a). At 21 hpi, the time of administration of antibiotic,
the mean clinical score, indicating health, was also greater for
the serotype 7F than the serotype 6B strain (p, 0.0001;
figure 1b). There was no difference in weight change between
the groups receiving the serotype 6B strain and the 7F strain at
21 hpi (97.1% and 97.4% of initial weight respectively) or
45 hpi (95.8% and 96.7% of initial weight respectively). Greater
survival of rats receiving serotype 7F than 6Bwas also seen in an
additional experiment when strain 106.66cps106.66 (serotype
6B) or strain 106.66cpsB109.15 (serotype 7F) were administered
(electronic supplementary material, figure S1).3.2. Serotype 6B caused more cortical injury than
serotype 7F
Of the rats which survived to 45 hpi, 7/13 which received the
serotype 6B strain developed cortical damage compared with
2/23 which received serotype 7F (Fisher’s exact test, p ¼
0.0049). The extent of cortical damagewas also greater in the ser-
otype 6B than the 7F group (figure 2, mean 15.2% versus 0.4%
respectively, p ¼ 0.0006). This may be an underestimate since
rats that died before 45 hpi were not included and these are
likely to have the most cortical damage. The number of apopto-
tic cells in the hippocampus of animals surviving until 45 hpi
was also determined, but no significant differencewas observed
between the two groups (mean values of 2.2 versus 1.0 for the
groups which received serotype 6B and 7F, respectively, p ¼
0.246). More cortical damage was also seen with the backtrans-
formant (serotype 6B) than the alternative serotype 7F capsule
switch mutant 106.66cpsB109.15 (electronic supplementary
material, figure S2). The mean number of apoptotic cells in the
hippocampus of rats that survived to 45 hpi was higher in
those which had received the backtransformant (serotype 6B)
than the serotype 7F capsule switch mutant 106.66cpsB109.15
(5.2 versus 0.09, respectively, p ¼ 0.0476 by Mann–Whitney).
3.3. Cerebrospinal fluid cytokine levels differed between
rats infected with serotypes 6B and 7F
CSF sampleswere taken at 21 and 45 hpi and tested for cytokine
concentrations. At 21 h, higher concentrations of cytokines IL-6
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Figure 3. (a– e) Cytokine concentrations in CSF at 21 hpi. Asterisk indicates significant difference from strain 106.66 (p , 0.005).
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serotype 6B than either the serotype 7F or the non-encapsulated
mutant groups (p, 0.05; figure 3a,b). TNFa and IL-10 concen-
trations were slightly higher following infection with 6B rather
than 7F but not significantly, although significantly higher than
the non-encapsulatedmutant (figure 3c,d). In contrast, IFNg con-
centration was greater in the CSF of the rats that received the
serotype 7F strains than either the 6B or the non-encapsulated
groups (p, 0.05; figure 3e). At 21 h, the mean concentration of
IL-6 and IL-1b was also higher for the backtransformant (sero-
type 6B) than the alternative capsule switch mutant of serotype
7F (electronic supplementary material, figure S3), although
owing to the low number of animals the data did not reach sig-
nificance. At 45 hpi, levels of all cytokines tested were below
the limit of detection in CSF samples of all rats, regardless of the
serotype of the infecting pneumococcal strain (data not shown).3.4. Correlations between bacterial load, cytokine
concentrations and cortical damage
It was noted that the cytokine concentrations induced by the
serotype 6B strain 106.66 in figure 3 were spread over a wide
range and so we looked for correlations between bacterial
load, cytokine concentrations and cortical damage (figure 4).
IL-6 concentration in the CSF at 21 h did correlate with CFU
in the CSF (figure 4a) and also percentage of cortical injury at45 hpi (figure 4b). The same pattern was seen with IL-1b
which also correlated with both CFU (figure 4c) and cortical
injury (figure 4d ). This also meant that there was a correlation
between CFU and cortical injury (figure 4e). Spearman corre-
lation r-values ranged between 0.6485 and 0.9152 and all
p-values were, 0.05.3.5. Serotype 6B, but not 7F, maintained a thick
capsule in the cerebrospinal fluid
Bacteria from the inoculum, grown in BHI, were viewed
microscopically in the presence of FITC-dextran, according
to the established method [15], to visualize capsule thickness.
Although quantitative measurements were not determined,
it was observed that both strains 106.66 (6B) and
106.66cps208.41 (7F) formed chains of relatively thickly encap-
sulated bacteria during this in vitro culture in rich medium
(figure 5a,b), although some variation in capsule thickness
was apparent in strain 106.66cps208.41 (figure 5b). However,
for bacteria recovered from the CSF at 21 hpi, there was a
striking difference in capsule thickness, with strain 106.66
(serotype 6B) able to maintain a thick capsule whereas
strain 106.66cps208.41 (7F) had a much thinner capsule
(figure 5c,d). Both strains in CSF were found predominantly
in pairs or individual bacteria rather than in chains. The back-
transformant 106.66cps106.66 (6B) also had a thick capsule in
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Figure 4. Correlations between bacterial load, cytokine concentrations and cortical damage. (a,b) IL-6 concentration in CSF at 21 hpi correlated with (a) CFU in the
CSF at 21 hpi (Spearman correlation r ¼ 0.9152, p ¼ 0.0005) and (b) percentage of cortical injury at 45 hpi (r ¼ 0.9116, p ¼ 0.0005). (c,d) IL-1b also correlated
with (a) CFU (r ¼ 0.6485, p ¼ 0.049) and (d ) cortical injury (r ¼ 0.7435, p ¼ 0.0196). (e) CFU at 21 hpi correlated with cortical injury at 45 hpi (r ¼ 0.8669,
p ¼ 0.0003).
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S4a,c), whereas the 106.66cpsB109.15 (7F) had a thinner capsule
in bothBHI andCSF (electronic supplementarymaterial, figure
S4b,d). 106.66cps106.66 (6B) and 106.66cpsB109.15 (7F) were
also found in pairs or individual bacteria in CSF compared
with chains in BHI.4. Discussion
It has been observed that some pneumococcal serotypes are
associated with worse clinical outcomes than others [10],
but it is unknown whether this is due directly to the capsule
type or to other factors of the disease-causing strains. Here,
we show that severity of meningitis in an infant rat meningi-
tis model does depend on the capsule type and that a capsule
is necessary to establish meningitis.Serotype 6B strains (wild-type clinical isolate or its back-
transformant capsule mutant) caused more severe disease
than either of two mutants expressing 7F capsule in the
same genetic background. Serotype 6B caused more mortality
than serotype 7F and this correlated with more cortical injury,
although not significantly more apoptotic cells in the hippo-
campus. Levels of inflammatory cytokines IL-6 and IL-1b in
the CSF at 21 h after infection were higher in rats infected
with serotype 6B than 7F, suggesting an association between
an exaggerated inflammatory response and worse outcome.
This was supported by the finding that within the group of
rats infected with the serotype 6B strain, there was a positive
correlation between IL-6 and IL-1b concentrations and
amount of cortical damage.
TNFa, IL-10 and IFNg were increased by both serotypes
with no difference between them for TNFa and IL-10 and a
higher level of IFNg in the serotype 7F group. Therefore,
10 mm
(b)(a)
(c) (d )
Figure 5. FITC-dextran analysis of capsule thickness. Capsule thickness was
determined in wild-type strain 106.66 (serotype 6B) (a,c) and capsule
switch mutant 106.66cps208.41 (serotype 7F) (b,d) growing in BHI before
inoculation of rats (a,b) and in CSF recovered from rats 21 h after infection
(c,d ), showing that the serotype 6B, but not the 7F, strain can maintain a
thick capsule in CSF. Original magnification ¼ 630, insets show close
ups of outer images. All outer images are to the same scale as each
other, and all insets are to the same scale as each other. Scale bar indicates
10 mm and refers to the outer images.
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tested, but the pattern of response of the different cytokines
varied by serotype.
While for most of the cytokines investigated our results
are in line with previous findings showing that high levels
of cytokines, particularly IL-6, in the CSF, are associated
with clinical severity and worsening of neurological long-
term sequelae [24,25], we observed a higher level of IFNg
in animals infected with the less virulent 7F serotype. This
is in contradiction to recent experimental results describing
IFNg as an important contributor to the pathogenesis of bac-
terial meningitis [26,27]. One study showed an association
between IFNg-driven acute brain pathology and the long-
term neurological sequelae resulting from pneumococcal
meningitis using IFNg knockout mice infected by a serotype
3 strain (WU2). In the other study, the survival of mice
infected with a serotype 4 strain (TIGR4) was prolonged
upon treatment with a neutralizing antibody directed against
IFNg. It is therefore conceivable that the relevance of IFNg
production in the pathogenesis of meningitis may be
serotype-specific or host-specific.
Although there was a difference in disease severity
between the two serotypes, both were able to establish
an infection in the rat model. This was in contrast to a non-
encapsulated mutant that did not establish an infection or
cause any detectable disease, indicating that a capsule is essen-
tial to establish an infection in this model of meningitis. This
is compatible with the fact that pneumococci lacking capsule
are rarely associated with invasive disease [28].Although the reason for the difference between the sero-
types in severity of meningitis they cause is unknown, it is
of note that there was a striking difference in capsule thick-
ness between the two serotypes when isolated from the
infected rats. While serotype 6B maintained a thick capsule
in the CSF, 7F had a much thinner capsule. This could be
because synthesis of the 6B capsule requires less metabolic
effort than the 7F, and this is reflected in capsule thickness
under nutrient-restricted conditions as we have shown
before in vitro [15]. Both serotypes changed from growth in
chains in the inoculum to pairs or individual bacteria in the
CSF. A thick capsule and reduction in chain length are both
mechanisms to reduce complement binding [29].
A strength of this study is that we compare serotypes in
the same genetic background, but a limitation is that we
have only looked at two serotypes: 6B commonly associated
with colonization and 7F with invasive disease, both sero-
types included in the Prevnar 13 and Pneumovax 23
vaccines. It would be of great interest to expand the study
to other serotypes to see whether serotypes associated with
colonization cause more severe meningitis in general than
serotypes associated with invasion. Varvio et al. [30]
described two lineages of serotypes based on evolution of
capsule regulatory genes: one ancestral and associated with
carriage (including serotype 6B) and the other with laterally
transferred sequences associated with invasive disease
(including serotype 7F). Although beyond the scope of this
study, a comparison of members of the two lineages in the
infant rat model may yield interesting findings in the future.
Using mutants with the same genetic background but
different serotypes allowed us to determine conclusively
that the capsule type affects severity of meningitis. In the cur-
rent era of vaccination against a subset of capsules, some
serotypes are increasing in colonization prevalence as compe-
tition from vaccine serotypes is removed [31]. Disease
potential of replacement serotypes should be a consideration
in vaccine design, because there is the possibility that disease
caused by replacement serotypes could be more severe than
that caused by serotypes included in the vaccines.
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